Keyphrases
Breathing Phases
28%
Clinical Target Volume
28%
Dose Deformation
14%
Dose Distribution
57%
Dose Engine
14%
Dose Evaluation
14%
Dose-volume Parameters
14%
Dosimetric Effects
14%
Evaluation Approach
14%
Evaluation Strategy
100%
Four-dimensional Computed Tomography
57%
Hyperscanning
14%
Individual Phases
28%
Intensity-modulated Proton Therapy
14%
Internal Target Volume
85%
Large Tumors
28%
Large-scale Motions
100%
Lung Cancer Patients
14%
Lung Tumor
100%
Medical Systems
14%
MeV Ions
28%
Monte Carlo
14%
Motion Amplitude
100%
Organs at Risk
28%
Overdosage
14%
Patient Selection
14%
Patient with Tumor
14%
Plan Evaluation
14%
Planning Strategy
42%
Proton
14%
Proton Therapy
100%
Ranging Error
14%
RayStation
14%
Reference Phase
14%
Respiratory Motion
14%
Risk Constraints
14%
Robust Optimization
14%
Robustness Evaluation
100%
Setup Error
14%
Stockholm
14%
Sweden
14%
Target Coverage
14%
Treatment Dose
14%
Treatment Planning
100%
Tumor
42%
Tumor Coverage
14%
Underdosage
14%
Volume-based
14%
Volume-targeted
14%
Voxel-wise
42%
Weighted Sums
28%
INIS
accuracy
9%
amplitudes
100%
breathing
18%
cancer
9%
comparative evaluations
9%
computed tomography
36%
computerized tomography
36%
constraints
9%
deformation
9%
dose distributions
36%
doses
90%
engines
9%
errors
18%
evaluation
100%
four-dimensional calculations
36%
laboratories
9%
losses
9%
lungs
100%
monte carlo method
9%
motion
100%
optimization
9%
organs
18%
patients
36%
planning
100%
protons
100%
range
9%
risks
18%
sweden
9%
therapy
100%
tumors
100%
usa
9%
volume
100%
Medicine and Dentistry
Breathing
28%
Four Dimensional Computed Tomography
57%
Lung Cancer
14%
Lung Tumor
100%
Neoplasm
100%
Patient Selection
14%
Proton Therapy
100%
Treatment Planning
100%
Biochemistry, Genetics and Molecular Biology
Breathing
50%
Four Dimensional Computed Tomography
100%
Motion
100%
Radiation Dose Distribution
100%
Computer Science
Cancer Patient
25%
Dose Distribution
100%
Evaluation Approach
25%
Reference Phase
25%
Risk Constraint
25%
Robust Optimization
25%
Pharmacology, Toxicology and Pharmaceutical Science
Lung Cancer
14%
Lung Tumor
100%
Neoplasm
100%